The trajectory of companies tied to iconic drugs like Viagra presents a complex investment picture. While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the expiry in key regions has introduced substantial volatility. Investors are now assessing the effect of rival medications , reduced inco